Aileron Therapeutics to Host Key Opinion Leader Event on February 15, 2024
Aileron Therapeutics, Inc. will host a virtual key opinion leader event to discuss LTI-03, a novel Caveolin-1-related peptide for the treatment of idiopathic pulmonary fibrosis. The event will feature a panel discussion with pulmonary care medicine experts and will focus on emerging therapies, including LTI-03. Aileron's pipeline of first-in-class medicines aims to address unmet medical needs in orphan pulmonary and fibrosis indications.
02/01/2024 - 04:30 PM
Panel discussion will highlight LTI-03, Aileron’s novel Caveolin-1-related peptide, for the treatment of idiopathic pulmonary fibrosis
WALTHAM, Mass., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Aileron Therapeutics, Inc. (“Aileron”) (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced that it will host a virtual key opinion leader event titled, “Clinical Perspectives on Treating Idiopathic Pulmonary Fibrosis” on Thursday, February 15, 2024, from 4:30 to 5:30 p.m. ET.
Aileron management will be joined by pulmonary care medicine experts including:
Fernando J. Martinez, M.D., M.S., Chief of the Pulmonary and Critical Care Medicine Division at Weill Cornell Medicine Tejaswini Kulkarni, M.D., M.P.H., Associate Professor of Pulmonology, Allergy and Critical Care Medicine and Director of the Interstitial Lung Disease Program at University of Alabama at Birmingham Medicine Andreas Günther, M.D., Senior Physician of Pulmonology and Intensive Care Medicine and Chief Physician of Pulmonology and Internal Intensive Care Medicine at Agaplesion Evang. Central Hesse Hospital; Professor of Interstitial and Rare Lung Diseases at Justus Liebig University The event will include a panel discussion of emerging therapies including LTI-03, Aileron’s novel Caveolin-1-related peptide with a dual mechanism targeting alveolar epithelial cell survival and inhibition of profibrotic signaling, followed by a question-and-answer panel with the physicians.
To access the event, please dial +1 646-876-9923 (domestic) or +44 208-080-6591 (international) and reference webinar ID: 953 9620 1729 and passcode: 554257 when prompted by the operator. A live webcast of the event can be accessed at https://investors.aileronrx.com/events-presentations/investor-events . A replay of the webcast will be available following the completion of the event.
About Aileron Therapeutics
Aileron Therapeutics is a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications. Aileron's lead product candidate, LTI-03, is a novel, synthetic peptide with a dual mechanism targeting alveolar epithelial cell survival as well as inhibition of profibrotic signaling. Currently, LTI-03 is being evaluated in a Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis, with topline results expected to be reported by the end of 2Q24. Aileron's second product candidate, LTI-01, is a proenzyme that has completed Phase 1b and Phase 2a clinical trials for the treatment of loculated pleural effusions. LTI-01 has received Orphan Drug Designation in the US and EU and Fast Track Designation in the US.
Investor Relations & Media Contact: Argot Partnersaileron@argotpartners.com
What is the focus of Aileron Therapeutics' virtual key opinion leader event?
The event will highlight LTI-03, Aileron's novel Caveolin-1-related peptide for the treatment of idiopathic pulmonary fibrosis.
When will the virtual key opinion leader event take place?
The event is scheduled for Thursday, February 15, 2024, from 4:30 to 5:30 p.m. ET.
Who will be joining Aileron management at the event?
Pulmonary care medicine experts including Fernando J. Martinez, Tejaswini Kulkarni, and Andreas Günther will participate in the panel discussion.
What is the dual mechanism of action of LTI-03?
LTI-03 targets alveolar epithelial cell survival and inhibits profibrotic signaling.
How can the event be accessed?
The event can be accessed via phone or live webcast. Details are available at https://investors.aileronrx.com/events-presentations/investor-events.
ALRN Rankings
N/A Ranked by Stock Gains
ALRN Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Health Technology, Pharmaceuticals: Major, Manufacturing, Pharmaceutical Preparation Manufacturing
About ALRN
aileron is the clinical-stage leader in the field of stapled peptide therapeutics for cancers and other diseases. our lead product candidate, alrn-6924, which is being evaluated in multiple clinical trials, reactivates p53-mediated tumor suppression by targeting both of the primary p53 suppressor proteins mdmx and mdm2. the p53 protein, often referred to as the “guardian of the genome,” is known for its central role in preventing cancer initiation and progression, and its inactivation is essential for the formation of virtually all cancers. we believe that alrn-6924 is the first and only product candidate in clinical development that can inhibit both mdmx and mdm2, which we believe, based on published data and our preliminary clinical results, are equally important in restoring p53 function as the body’s first line of defense against cancer. based on preclinical data and preliminary evidence of safety and anti-tumor activity in our ongoing clinical trials, we believe there may be a sig
